1007205-44-8

Upstream product

• 96-48-0 4-butanolide 
• 1711-05-3 m-anisoyl chloride 

Downstream Products

• 1007205-45-9 5-(2-hydroxyethyl)-6-(3-methoxyphenyl)-2-morpholin-4-yl-pyrimidin-4-ol 
• 1007205-48-2 4-(3-methoxy-phenyl)-2-morpholin-4-yl-7-pyridin-3-yl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 
• 1007205-43-7 4-(3-methoxy-phenyl)-2-morpholin-4-yl-7-pyridin-4-yl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 
• 1007205-56-2 3-(2-morpholin-4-yl-7-pyridin-3-yl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-phenol 
• 1007205-55-1 3-(2-morpholin-4-yl-7-pyridin-4-yl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-phenol 
• 1267952-72-6 4-oxo-4-(3-methoxyphenyl)-1-butanol 
• 38102-79-3 (+)-(R)-γ-(3-methoxyphenyl)-γ-butyrolactone 

Relevant academic research and scientific papers

Lead optimization of a dihydropyrrolopyrimidine inhibitor against phosphoinositide 3-kinase (PI3K) to improve the phenol glucuronic acid conjugation

Our lead compound for a phosphoinositide 3-kinase (PI3K) inhibitor (1) was metabolically unstable because of rapid glucuronidation of the phenol moiety. Based on structure-activity relationship (SAR) information and a FlexSIS docking simulation score, aminopyrimidine was identified as a bioisostere of phenol. An X-ray structure study revealed a hydrogen bonding pattern of aminopyrimidine derivatives. Finally, aminopyrimidine derivatives 33 showed strong tumor growth inhibition against a KPL-4 breast cancer xenograft model in vivo.

Enantioselective ketone hydroacylation using noyori's transfer hydrogenation catalyst

An enantioselective ketone hydroacylation enables the direct preparation of lactones from keto alcohols. The alcohol is oxidized in situ to an aldehyde, obviating the need to prepare sensitive keto aldehyde substrates. Noyori's asymmetric transfer hydroge

Discovery and biological activity of a novel class i PI3K inhibitor, CH5132799

Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase and a promising therapeutic target for cancer. Using structure-based drug design (SBDD), we have identified novel PI3K inhibitors with a dihydropyrrolopyrimidine skeleton. Metabolic stability of the first lead series was drastically improved by replacing phenol with aminopyrimidine moiety. CH5132799, a novel class I PI3K inhibitor, exhibited a strong inhibitory activity especially against PI3Kα (IC50 = 0.014 μM). In human tumor cell lines with PI3K pathway activation, CH5132799 showed potent antiproliferative activity. CH5132799 is orally available and showed significant antitumor activity in PI3K pathway-activated human cancer xenograft models in mice.

PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF

A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, rep